Immune-related adverse events are associated with better event-free survival in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage triple-negative breast cancer
Rios-Hoyo A, Dai J, Noel T, Blenman K, Park T, Pusztai L. Immune-related adverse events are associated with better event-free survival in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage triple-negative breast cancer. ESMO Open 2025, 10: 104494. PMID: 40107153, PMCID: PMC11964624, DOI: 10.1016/j.esmoop.2025.104494.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsTriple-negative breast cancerEvent-free survivalResidual cancer burdenDevelopment of immune-related adverse eventsOverall survivalAdverse eventsLandmark analysisAssociated with better event-free survivalBreast cancerEarly-stage triple-negative breast cancerFrequent immune-related adverse eventsMultiple immune-related adverse eventsEvent-free survival eventsRCB 0Immune checkpoint inhibitor therapyPhase I/II clinical trialsPathological complete responseSingle-arm clinical trialCheckpoint inhibitor therapyImmune checkpoint therapyMedian Follow-UpTime of surgeryYale Cancer CenterAdministered post-operatively
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply